Nipro (TYO: 8086) subsidiary Infraredx said today that it won expanded FDA 510(k) clearance for its Makoto intravascular imaging system, now cleared to identify patients and coronary plaques at an increased risk of major adverse cardiac events. The approval came based on results from the Lipid-Rich Plaque study in which researchers explored the ability of intravascular […]
Nipro
Aegea Medical picks up former Cardiokinetix, Concentric Medical CEO Sainz | Personnel Moves – May 14, 2018
Aegea Medical said last week it tapped former Cardiokinetix prez & CEO Maria Sainz as its new president and chief executive officer, effective immediately. Sainz will replace former CEO Don Gurskis, who has held the corner office since 2013. Gurskis will remain on as member of the Redwood City, Calif.-based company’s executive management team. “Maria is […]
Nipro launches 2nd-gen guidewire, OTW balloon cath in U.S.
Nipro (TYO: 8086) said this week it launched its Cronus HP high-pressure over-the-wire balloon catheter and its AquaLiner II 2nd-gen hydrophilic nitinol guidewire in the U.S. The Japanese company’s Chronus HP is a 0.035″ percutaneous transluminal angioplasty balloon catheter with indications for percutaneous transluminal angioplasty in the femoral, popliteal, iliac and renal arteries for treating obstructive […]
Sinocare closes $273m Nipro buy
Nipro (TYO: 8086) said today it closed the $273 million sale of its diagnostics business to China-based Sinocare, which renamed the newly acquired company to Trividia Health. Former Nipro Diagnostics CEO and chair Scott Verner will stay on as CEO and prez of Trividia health, joined by “key executives” from the current management team, according to the press release. […]
Nipro to sell diagnostics biz to China’s Sinocare for $273m
Nipro (TYO: 8086) said today it signed a deal sell its diagnostics business to China-based Sinocare for approximately $273 in cash. Nipro Diagnostics, based in Ft. Lauderdale, Fla., develops, manufactures and markets diabetes products, including glucose monitors, the company said. “This transaction combines 1 of the fastest growing blood glucose monitoring companies in the United States with […]
Nipro to acquire Infraredx
Nipro (TYO: 8086) said today that it plans to acquire Infraredx and its cardiovascular imaging device for an undisclosed amount. Burlington, Mass.-based Infraredx makes an imaging system that combines intravascular ultrasound and near-infrared spectroscopy to provide images of the interior of coronary blood vessels. The company says the device is designed to detect lipid-core-containing plaque, which it […]
China halts anti-dumping probe into EU, Japan dialysis kit makers
Diabetes: Nipro Dx boosts manufacturing following FDA wins for blood glucose monitors
Diabetes company Nipro Diagnostics touted FDA wins for a pair of new blood glucose monitors for use in home and professional settings, saying that the device maker will look to boost its manufacturing capabilities ahead of a late 2014 launch.
Press Release: Nipro Diagnostics, Inc. announces FDA clearance of its newest blood glucose monitoring systems
FORT LAUDERDALE, Fla. – Nipro Diagnostics, Inc., today announced that the U.S. Food and Drug Administration (FDA) has cleared its True Metrix Self-Monitoring blood glucose system and the True Metrix Pro Professional Monitoring blood glucose system.
Nipro puts $25M into Infraredx
Infraredx said Nipro Corp. (TYO:8086) put down a $25 million equity investment in the Burlington, Mass.-based medical device company and its TVC intravascular imaging system.
The deal builds on an existing distribution contract in Japan between Infraredx and Nipro, according to a press release, and will a Nipro representative join the Infraredx board.
U.S. orthopedics on the upswing, analysts say | Wall Street Beat
Wall Street analysts are predicting with increasing confidence that the U.S. orthopedics market is on the upswing following an industry survey suggesting a coming increase in procedure volumes.
A MEDACorp orthopedics survey of 65 U.S. hip and knee surgeons found improvements in 12-month procedure volume expectations and increased patient willingness for surgery, according to an investment note from Leerink Swann analyst Richard Newitter.
